MarketIQ Analyst Report for Lifecore Biomedical Inc.

3603 HAVEN AVE, MENLO PARK, CA, US
LFCR

Last Updated: 19 Sep 2024

Executive Summary

Lifecore Biomedical Inc. (LFCR) is a contract development and manufacturing organization that provides services to the medical device and pharmaceutical industries. The company has a market capitalization of $160.67 million and trades on the NASDAQ exchange. LFCR's latest stock price is $5.62.

Company Overview

Lifecore Biomedical was founded in 1989 and is headquartered in Santa Maria, California. The company has operations in the United States, Europe, and Asia. LFCR provides a range of services, including product development, manufacturing, and regulatory support. The company's customers include some of the world's largest medical device and pharmaceutical companies.

Fundamental Analysis

LFCR's financial performance has been mixed in recent years. The company's revenue has grown steadily, but its profitability has declined. In 2023, LFCR reported revenue of $128.26 million and net income of $1.17 million. The company's gross profit margin was 21.3%, and its operating margin was 7.6%. LFCR's balance sheet is strong. The company has no debt and has a cash balance of $22.6 million. LFCR's book value is $0.37 per share.

Technical Analysis

LFCR's stock price has been in a downtrend since early 2023. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is also below 50, indicating that the stock is oversold.

Short Term Outlook

LFCR's stock price is likely to remain under pressure in the short term. The company's financial performance has been mixed, and the stock is trading below its moving averages. The RSI is also below 50, indicating that the stock is oversold.

Long Term Outlook

LFCR's long-term outlook is more positive. The company has a strong balance sheet and a growing customer base. The medical device and pharmaceutical industries are expected to continue to grow in the coming years, which should benefit LFCR.

Analyst Recommendations

The majority of analysts have a hold rating on LFCR. The average analyst target price is $6.50.